Triptolide inhibits the multidrug resistance in prostate cancer cells via the downregulation of MDR1 expression

Q. GUO1,2,‡, X. X. NAN1,‡, J. R. YANG1,4*, L. YI1, B. L. LIANG1, Y. B. WEI1, N. ZHU1, S. B. HU1, H. ZHANG2, Y. LUO2, Y. F. XU2

1Department of Urology, Second Xiangya Hospital, Central South University, 410011, Changsha, China; 2Department of Urology, The Third Hospital Of Changsha, 410015, Changsha, China

*Correspondence: yangjinrui33@163.com
‡Contributed equally to this work.

Received December 11, 2012 / Accepted March 20, 2013

Triptolide (TPL) is a diterpenoid triepoxide derived from the Chinese herb Tripterygium wilfordii and possesses anti-tumor activity against a range of cancer cells. However, the effect of TPL on prostate cancer cells and its potential to overcome multidrug resistance (MDR) have not been explored. Therefore, in this study we used prostate cancer cell line DU145 as the experimental model and established DU145/ADM cell line resistant to adriamycin (ADM). Our results showed that TPL inhibited the proliferation and induced the cell cycle arrest and apoptosis of DU145 cells in a dose and time dependent manner. TPL decreased the levels of Cyclin D1 and anti-apoptotic protein Bcl-2, and increased the levels of pro-apoptotic proteins Fas and Bax. Furthermore, we found that TPL restored the sensitivity DU145/ADM cells to ADM in a dose dependent manner, and this was accompanied by the inhibition of MDR1 expression at both mRNA and protein levels. Taken together, these results provide strong evidence that TPL overcomes MDR in prostate cancer cells by downregulating MDR1 expression, and suggest that TPL is a promising agent for prostate cancer therapy, especially for chemoresistant prostate cancer.

Key words: MDR1, multidrug resistance, prostate cancer, triptolide, apoptosis

Prostate cancer is a form of malignancy that frequently develops in older males and is one of the leading causes of cancer death in men. Recently, great progress has been made in the prevention, detection and prognosis of patients with prostate cancer [1-4]. However, prostate cancer is known to exhibit the ability to metastasize to other parts of the body, particularly the bones, and develop resistance to chemotherapy. Therefore, the effective treatment for prostate cancer is still a challenge in the clinic. Multidrug resistance (MDR) is a common mechanism for tumor cells to overcome the cytotoxicity of a broad spectrum of anticancer agents, and remains a major obstacle to cancer chemotherapy. P-glycoprotein, also known as multidrug resistance protein 1 (MDR1), is encoded by mdr1 gene and plays important role in MDR [5, 6]. Accumulating evidence has suggested that MDR1 is a potential target to overcome MDR and increase the sensitivity of tumor cells to chemotherapy. Interestingly, phytochemicals derived from Chinese herbs emerged as new candidates of P-glycoprotein inhibitors and showed promise in cancer therapy to overcome MDR [7].

Triptolide (TPL) is a diterpenoid triepoxide extracted from the Chinese herb Tripterygium wilfordii Hook f. which has been used for centuries as Chinese traditional herbal remedies for autoimmune and inflammatory diseases [8]. Recent studies have shown that TPL possesses anti-tumor activity by inhibiting the proliferation and inducing the apoptosis in a variety of cancer cells including prostate cancer cells [9-12]. However, the effect of TPL on drug-resistant prostate cancer cells and its potential to overcome MDR have not been explored. Therefore, in this study we used prostate cancer cell line DU145 as the experimental model and established DU145/ADM cell line resistant to adriamycin (ADM). We examined the effects of TPL on the proliferation and apoptosis of DU145/ADM cells.

Materials and methods

Cells and cell culture. The human prostate cancer cell line DU145 was obtained from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai,
DU145 or DU145/ADM cells were seeded in 6-well plates and cultured overnight. The cells were then treated with TPL at different concentrations (20, 40, 80 ng/ml) for 72 h, washed twice with ice-cold PBS. Lysate was extracted from the cells using RIPA, Lysis Buffer and the protein concentration of the lysate was measured using a BCA Protein Assay Kit (Pierce, USA). Equal amounts of lysate (50 μg protein) were separated by 12% SDS-PAGE and transferred onto PVDF membranes (Pierce, USA). The membranes were blocked with 5% nonfat milk for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against MDR1, Cyclin D1, Bcl-2, Bax, Fas, cleaved Caspase-3 or β-actin (Santa Cruz, USA). The membranes were washed 3 times for 15 min in TBS containing 0.05% Tween-20, and then incubated with horseradish peroxidase conjugated secondary antibodies (Santa Cruz, USA) at room temperature for 1 h. Positive immunoreactions were detected using Super Signal West Pico Chemiluminescent Substrate (Thermo, USA) and exposed to X-ray films.

Statistical analysis. Data were expressed as the mean±SD and analyzed using the SPSS version 12 statistical analysis package (SPSS Inc., Chicago, IL, USA). P<0.05 was accepted as statistically significant.

Results

TPL inhibits the proliferation and induces the apoptosis of DU145 cells. First we examined the effects of TPL on the proliferation and apoptosis of prostate cancer cells. We treated DU145 cells with different concentrations of TPL (20, 40, 80 ng/ml) for 24 h, 48 h, or 72 h and performed MTT assay. The results showed that TPL inhibited the proliferation of DU145 cells in a dose and time dependent manner (Fig. 1). The IC50 of TPL for DU145 cells at 24 h, 48 h and 72 h were 40, 27 and 17 nmol/L, respectively. Since TPL exhibited the most significant inhibitory effects on DU145 cell proliferation...
after treatment for 72 h, we chose 72 h as the time point for the following experiments.

Next we performed flow cytometry analysis to examine the apoptosis of DU145 cells treated by TPL. Flow cytometry analysis showed that TPL induced the apoptosis of DU145 cells in a dose dependent manner at 72 h (Fig. 2). The apoptosis rate of DU145 cells after treatment with 0, 20, 40, and 80 ng/ml TPL was 6.3±0.97%, 26.7±1.08%, 29.0±1.21% and 41.6±1.66%, respectively, and the differences in apoptosis rate between control and TPL treated cells were significant (p< 0.05).

We further examined the cell cycle phase distribution of DU145 cells after treatment with 0, 20, 40, and 80 ng/ml TPL for 72 h. Flow cytometry analysis showed that TPL induced S phase arrest in DU145 cells in a dose dependent manner (Fig. 3). Collectively, these data suggest that TPL inhibits prostate cancer cell growth by inducing S phase arrest and apoptosis.

**TPL modulates the expression of cell cycle and apoptosis associated proteins in DU145 cells.** To explore the molecular mechanism by which TPL induces the cell cycle arrest and apoptosis of DU145 cells, DU145 cells were treated with 20, 40, or 80 ng/ml TPL for 72 h and subjected to Western blot analysis. The results showed that TPL decreased the protein level of cyclin D1. For apoptosis associated proteins, TPL increased the protein level of Fas and Bax, and decreased the protein level of Bcl-2. In addition, the protein level of cleaved Caspase-3 was increased after TPL treatment, indicating increased apoptosis (Fig. 4). Taken together, these results suggest that TPL modulates the expression of cell cycle and apoptosis associated proteins to regulate cell cycle and apoptosis of prostate cancer cells.

**TPL overcomes MDR in DU145/ADM cells.** To investigate the effects of TPL on MDR, we treated DU145/ADM cells with 20, 40, or 80 ng/ml TPL together with 10, 20, 30, 40 or 50 ng/ml ADM for 72 h simultaneously. The results demonstrated that TPL increased the sensitivity of DU145/ADM cells to ADM induced cell proliferation inhibition in a dose and time dependent manner (Fig. 5). These data suggest that TPL may overcome MDR in prostate cancer cells.

**TPL inhibits MDR1 expression in DU145/ADM cells.** To elucidate the molecular mechanisms by which TPL overcomes MDR in prostate cancer, we examined the expression of MDR1 in DU145/ADM cells. As expected, RT-PCR and Western blot analysis showed that the expression of MDR1 at both mRNA and protein levels in drug resistant DU145/ADM cells was much higher than in DU145 cells (Fig. 6). However, when DU145/ADM cells were treated with TPL for 72 h, the expres-
TRIPTOLIDE INHIBITS MDR IN PROSTATE CANCER

Figure 3. TPL induces the S phase arrest of DU145 cells. DU145 cells were treated with DMSO (NC), 20, 40 or 80 ng/ml TPL for 72 h, and cell cycle distribution was detected by flow cytometry analysis. A-D: Representative flow histograms showing the cell cycle profiling of DU145 cells treated with TPL at the indicated concentration. E: Quantization of the cells in different phases. F: Quantization of the cells in S phase. *p<0.05 versus NC. **p<0.01 versus NC.

Expression of MDR1 at both mRNA and protein levels was decreased in a dose dependent manner (Fig. 6). Taken together, these results indicate that MDR1 overexpression contributes to MDR in prostate cancer cells and TPL overcomes MDR in prostate cancer cells by inhibiting the expression of MDR1.

Discussion

Chemotherapy has been widely used for the treatment of cancer and encouraging results have been achieved in some circumstances [13-15]. However, MDR has become one of the major problems for the effective treatment of tumors with chemotherapeutic agents, which is mainly resulted from the expression of transporters that remove the chemotherapeutic agents from the cytoplasm. In particular, the transporter P-glycoprotein encoded by the multidrug resistance 1 gene mdr1 is one of the most important mechanisms that contribute to MDR [5,6]. Interestingly, phytochemicals derived from Chinese herbs have shown promise in overcoming MDR in cancer therapy [7].

Figure 4. TPL modulates the expression of cell cycle and apoptosis associated proteins in DU145 cells. DU145 cells were treated with DMSO (NC), 20, 40, or 80 ng/ml TPL for 72 h and subjected to Western blot analysis. Shown were representative blots from three independent experiments with similar results. β-actin was used as loading control.
In this study, we first investigated the effects of TPL on prostate cancer cell proliferation and apoptosis. Our results showed that TPL inhibits the proliferation and induces the apoptosis of DU145 cells, consistent with previous studies which showed that TPL possesses anti-tumor activity by inhibiting the proliferation and inducing the apoptosis in cancer cells [9-12]. Flow cytometry analysis showed that TPL induced S phase arrest in DU145 cells in a dose dependent manner. Thus we propose that TPL inhibits prostate cancer cell growth by inducing S phase arrest and apoptosis.

Next we examined the effects of TPL on the expression of cell cycle and apoptosis associated proteins in DU145 cells. Our results showed that TPL decreased the protein level of Cyclin D1. Cyclin D1 serves as an active switch in the regulation of cell cycle and increased cyclin D1 synthesis would promote continued cell cycle progression [16]. As expected, reduced intracellular cyclin D1 level after TPL treatment would hinder the cell cycle progression and lead to S phase arrest in DU145 cells. On the other hand, our results showed that TPL increased the levels of pro-apoptotic proteins such as Fas and Bax, and decreased the level of anti-apoptotic protein Bcl-2. The cleavage of pro-Caspase-3 is a marker of the execution of apoptosis [17]. Our finding that TPL increased the level of cleaved Caspase-3 serves as additional evidence that TPL modulates the expression of apoptosis associated proteins to promote the apoptosis of prostate cancer cells.

Finally, we established drug resistant DU145/ADM cells by treating parent DU145 cells with ADM. We found that after
TPL treatment, DU145/ADM cells recovered the sensitivity to ADM treatment in a dose dependent manner, and this was accompanied by decreased MDR1 expression at both mRNA and protein levels. Taken together, these results provide strong evidence that TPL overcomes MDR in prostate cancer cells by downregulating the expression of MDR1. In fact, TPL was shown to decrease the expression of MDR in KB cancer cells [18]. Furthermore, TPL was capable of inhibiting the transcriptional activity of MDR1 promoter, and thus reversed adriamycin resistance in leukemia cells via modulation of P-glycoprotein expression [19]. A recent study reported that perifosine, a new Akt inhibitor, could reverse MDR partially via the downregulation of MDR1 expression in MCF-7/ADM breast cancer cells [20]. Notably, TPL exhibited the ability to inactivate Akt in cancer cells [21]. Therefore, we postulate that TPL may inhibit PI3K/Akt pathway to downregulate MDR1 expression. Further studies are needed to elucidate the molecular mechanisms by which TPL suppresses the expression of MDR1.

Interestingly, a previous study showed that the monoterprenoids extracted from the essential oil of Zanthoxyli fructus could inhibit P-gp (MDR1) directly [22]. TPL is a diterpenoid triepoxide extracted from the herb Tripterygium wilfordii and has a molecular structure similar to the monoterprenoids. Therefore, it remains to be determined whether TPL has the ability to inhibit the function of MDR1, which would provide new insight into the action of TPL to overcome MDR in cancer cells.

In conclusion, our data demonstrate that TPL inhibits the proliferation and induces the apoptosis of prostate cancer cells. Most importantly, TPL could reverse MDR1 mediated MDR in ADM resistant prostate cancer cells via the downregulation of MDR1 expression. These results suggest that TPL is a promising agent for prostate cancer therapy, especially for chemoresistant prostate cancer.

Acknowledgements: This study was supported by Pilot funds for Technology Transfer from Science and Technology Bureau of Changsha (No. K0904151-11).

References


